Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration

Gebran Khneizer, Ahmad Al-Taee, Bahar Bastani *

Cited by CrossRef: 7

1- Hanna R, Tran N, Patel S, Hou J, Jhaveri K, Parikh R, Selamet U, Ghobry L, Wassef O, Barsoum M, Bijol V, Kalantar-Zadeh K, Pai A, Amin A, Kupperman B, Kurtz I. Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use. Front Med. 2020;7 [Crossref]

2- Phadke G, Hanna R, Ferrey A, Torres E, Singla A, Kaushal A, Kalantar-Zadeh K, Kurtz I, Jhaveri K. Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration. 2021;14(10):2158 [Crossref]

3- Kenworthy J, Davis J, Chandra V, Clark J, Desmond M. Worsening Proteinuria Following Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema. Journal of VitreoRetinal Diseases. 2019;3(1):54 [Crossref]

4- Grechukhina K, Chebotareva N, Krasnova T. Nephrotoxicity of anti-angiogenesis drugs. Terapevticheskii arkhiv. 2020;92(6):93 [Crossref]

5- Yang S, Su Y, Lim C, Huang J, Hsu S, Wu L, Chang Y, Hung J. Risk of dialysis in patients receiving intravitreal anti–vascular endothelial growth factor treatment: a population-based cohort study. Aging. 2022;14(12):5116 [Crossref]

6- Hanna R, Lopez E, Hasnain H, Selamet U, Wilson J, Youssef P, Akladeous N, Bunnapradist S, Gorin M. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. 2019;12(1):92 [Crossref]

7- Hanna R, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney International. 2019;96(3):572 [Crossref]

8- Shye M, Hanna R, Patel S, Tram-Tran N, Hou J, Mccannel C, Khalid M, Hanna M, Abdelnour L, Kurtz I. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. 2020;13(6):969 [Crossref]

9- Bevacizumab. Reactions Weekly. 2017;1657(1):80 [Crossref]

10- Hanna R, Ahdoot R, Kim M, Jhaveri K, Kalantar-Zadeh K, Kurtz I. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review. 2022;31(1):47 [Crossref]

11- Grechukhina K, Chebotareva N, Zhukova L, Krasnova T. Clinical and laboratory signs and risk factors for nephrotoxicity, associated with antiangiogenic drugs. Terapevticheskii arkhiv. 2021;93(6):661 [Crossref]

12- Yau A, Conklin E, Campion V. Secondary Membranous in the Cancer Patient. Journal of Onco-Nephrology. 2022;6(1-2):29 [Crossref]